Management of patients with advanced prostate cancer in the Asia Pacific region

‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

Edmund Chiong, Declan G. Murphy, Hideyuki Akaza, Nicholas C. Buchan, Byung Ha Chung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Chi fai Ng, Teng Ong, Yeong Shiau Pu, Marniza Saad, Kathryn Schubach, Levent Türkeri, Rainy Umbas, Vu Le Chuyen, Scott Williams, Ding Wei Ye, ANZUP Cancer Trials Group & 1 others Ian D. Davis

Research output: Contribution to journalReview ArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Objective: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). Findings: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Although androgen receptor-targeting agents appear to be well tolerated in Asian men with metastatic castration-resistant prostate cancer, access to these drugs is very limited for financial reasons across the region. The meeting highlighted that cost and access to contemporary treatments and technologies are key factors influencing therapeutic decision-making in the APAC region. Whilst lower cost/older treatments and technologies may be an option, issues of culture and patient or physician preference mean, these may not always be acceptable. Although generic products can reduce cost in some countries, costs may still be prohibitive for lower-income patients or communities. The panellists noted the opportunity for a coordinated approach across the APAC region to address issues of access and cost. Developments in technologies and treatments are presenting new opportunities for the diagnosis and treatment of advanced prostate cancer. Differences in genetics and epidemiology affect the side-effect profiles of some drugs and influence prescribing. Conclusions: As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.

Original languageEnglish
Pages (from-to)22-34
Number of pages13
JournalBJU International
Volume123
Issue number1
DOIs
Publication statusPublished - Jan 2019

Keywords

  • advanced prostate cancer
  • castration-naïve prostate cancer
  • castration-resistant prostate cancer
  • cost and access to treatment
  • high-risk localised prostate cancer
  • oligometastatic prostate cancer

Cite this

Chiong, Edmund ; Murphy, Declan G. ; Akaza, Hideyuki ; Buchan, Nicholas C. ; Chung, Byung Ha ; Kanesvaran, Ravindran ; Khochikar, Makarand ; Letran, Jason ; Lojanapiwat, Bannakij ; Ng, Chi fai ; Ong, Teng ; Pu, Yeong Shiau ; Saad, Marniza ; Schubach, Kathryn ; Türkeri, Levent ; Umbas, Rainy ; Le Chuyen, Vu ; Williams, Scott ; Ye, Ding Wei ; ANZUP Cancer Trials Group ; Davis, Ian D. / Management of patients with advanced prostate cancer in the Asia Pacific region : ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. In: BJU International. 2019 ; Vol. 123, No. 1. pp. 22-34.
@article{b92cc03a7fd8445e848ed105385c8ef7,
title = "Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017",
abstract = "Objective: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). Findings: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-na{\"i}ve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Although androgen receptor-targeting agents appear to be well tolerated in Asian men with metastatic castration-resistant prostate cancer, access to these drugs is very limited for financial reasons across the region. The meeting highlighted that cost and access to contemporary treatments and technologies are key factors influencing therapeutic decision-making in the APAC region. Whilst lower cost/older treatments and technologies may be an option, issues of culture and patient or physician preference mean, these may not always be acceptable. Although generic products can reduce cost in some countries, costs may still be prohibitive for lower-income patients or communities. The panellists noted the opportunity for a coordinated approach across the APAC region to address issues of access and cost. Developments in technologies and treatments are presenting new opportunities for the diagnosis and treatment of advanced prostate cancer. Differences in genetics and epidemiology affect the side-effect profiles of some drugs and influence prescribing. Conclusions: As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.",
keywords = "advanced prostate cancer, castration-na{\"i}ve prostate cancer, castration-resistant prostate cancer, cost and access to treatment, high-risk localised prostate cancer, oligometastatic prostate cancer",
author = "Edmund Chiong and Murphy, {Declan G.} and Hideyuki Akaza and Buchan, {Nicholas C.} and Chung, {Byung Ha} and Ravindran Kanesvaran and Makarand Khochikar and Jason Letran and Bannakij Lojanapiwat and Ng, {Chi fai} and Teng Ong and Pu, {Yeong Shiau} and Marniza Saad and Kathryn Schubach and Levent T{\"u}rkeri and Rainy Umbas and {Le Chuyen}, Vu and Scott Williams and Ye, {Ding Wei} and {ANZUP Cancer Trials Group} and Davis, {Ian D.}",
year = "2019",
month = "1",
doi = "10.1111/bju.14489",
language = "English",
volume = "123",
pages = "22--34",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

Chiong, E, Murphy, DG, Akaza, H, Buchan, NC, Chung, BH, Kanesvaran, R, Khochikar, M, Letran, J, Lojanapiwat, B, Ng, CF, Ong, T, Pu, YS, Saad, M, Schubach, K, Türkeri, L, Umbas, R, Le Chuyen, V, Williams, S, Ye, DW, ANZUP Cancer Trials Group & Davis, ID 2019, 'Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017', BJU International, vol. 123, no. 1, pp. 22-34. https://doi.org/10.1111/bju.14489

Management of patients with advanced prostate cancer in the Asia Pacific region : ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. / Chiong, Edmund; Murphy, Declan G.; Akaza, Hideyuki; Buchan, Nicholas C.; Chung, Byung Ha; Kanesvaran, Ravindran; Khochikar, Makarand; Letran, Jason; Lojanapiwat, Bannakij; Ng, Chi fai; Ong, Teng; Pu, Yeong Shiau; Saad, Marniza; Schubach, Kathryn; Türkeri, Levent; Umbas, Rainy; Le Chuyen, Vu; Williams, Scott; Ye, Ding Wei; ANZUP Cancer Trials Group ; Davis, Ian D.

In: BJU International, Vol. 123, No. 1, 01.2019, p. 22-34.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Management of patients with advanced prostate cancer in the Asia Pacific region

T2 - ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

AU - Chiong, Edmund

AU - Murphy, Declan G.

AU - Akaza, Hideyuki

AU - Buchan, Nicholas C.

AU - Chung, Byung Ha

AU - Kanesvaran, Ravindran

AU - Khochikar, Makarand

AU - Letran, Jason

AU - Lojanapiwat, Bannakij

AU - Ng, Chi fai

AU - Ong, Teng

AU - Pu, Yeong Shiau

AU - Saad, Marniza

AU - Schubach, Kathryn

AU - Türkeri, Levent

AU - Umbas, Rainy

AU - Le Chuyen, Vu

AU - Williams, Scott

AU - Ye, Ding Wei

AU - ANZUP Cancer Trials Group

AU - Davis, Ian D.

PY - 2019/1

Y1 - 2019/1

N2 - Objective: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). Findings: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Although androgen receptor-targeting agents appear to be well tolerated in Asian men with metastatic castration-resistant prostate cancer, access to these drugs is very limited for financial reasons across the region. The meeting highlighted that cost and access to contemporary treatments and technologies are key factors influencing therapeutic decision-making in the APAC region. Whilst lower cost/older treatments and technologies may be an option, issues of culture and patient or physician preference mean, these may not always be acceptable. Although generic products can reduce cost in some countries, costs may still be prohibitive for lower-income patients or communities. The panellists noted the opportunity for a coordinated approach across the APAC region to address issues of access and cost. Developments in technologies and treatments are presenting new opportunities for the diagnosis and treatment of advanced prostate cancer. Differences in genetics and epidemiology affect the side-effect profiles of some drugs and influence prescribing. Conclusions: As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.

AB - Objective: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). Findings: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Although androgen receptor-targeting agents appear to be well tolerated in Asian men with metastatic castration-resistant prostate cancer, access to these drugs is very limited for financial reasons across the region. The meeting highlighted that cost and access to contemporary treatments and technologies are key factors influencing therapeutic decision-making in the APAC region. Whilst lower cost/older treatments and technologies may be an option, issues of culture and patient or physician preference mean, these may not always be acceptable. Although generic products can reduce cost in some countries, costs may still be prohibitive for lower-income patients or communities. The panellists noted the opportunity for a coordinated approach across the APAC region to address issues of access and cost. Developments in technologies and treatments are presenting new opportunities for the diagnosis and treatment of advanced prostate cancer. Differences in genetics and epidemiology affect the side-effect profiles of some drugs and influence prescribing. Conclusions: As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.

KW - advanced prostate cancer

KW - castration-naïve prostate cancer

KW - castration-resistant prostate cancer

KW - cost and access to treatment

KW - high-risk localised prostate cancer

KW - oligometastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85052790498&partnerID=8YFLogxK

U2 - 10.1111/bju.14489

DO - 10.1111/bju.14489

M3 - Review Article

VL - 123

SP - 22

EP - 34

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -